Purpose: A feasibility study was conducted to investigate whether synchronized intra-aortic chemotherapy (SIAC) could be a safe method, and improve quality of life of far advanced gastric cancer patients with tumor-related symptoms. Patients and Methods: Sixty-seven patients disordered their performance status with stage IV or recurrent gastric cancer localized to the abdominal cavity were entered in the study. SIAC regimen consisted of bolus intra-aortic injection (IA) of cisplatin 6 mg/m 2 /body and methotrexate 6 mg/m 2 /body per day on days 1 to 5 in the morning, followed by continuous IA of 5-fluorouracil 150 mg/m 2 /body/day for 5 days, and systemic infusion of l-leucovorin 15 mg/m 2 /body/day on days 2 to 6 at 8 PM, repeated every 3 weeks for the first three courses and every 1-3 months after the fourth course. Results: The response rate was 61% (CR 2, PR 37). The tumor control rate (CR+PR+NC) was 89%. Performance status were improved in 51% of the patients. The incidences of side effects of grade 3 or more was anorexia 8.9%, leucopenia 4.5%, and nausea 3.0%. Conclusion: These data suggest that SIAC regimen is safe and effective for response rate and performance status in patients with stage IV advanced gastric cancer, localized in the abdominal cavity.
Introduction
Palliative chemotherapy in patients with locally advanced and metastatic gastric cancer has gradually improved overall survival (OS) and relieved tumorrelated symptoms than the best supportive care (BSC). Fluoropyrimidine (5-fluorauracil 〈FU〉 , S-1, or capecitabine), platinum (cisplatin〈CDDP〉), taxane (paclitaxel or docetaxel), epirubicin, irinotecan and trastuzumab (targeted agents against the human epidermal growth factor receptor 2 〈HER2〉 ) are used for the treatment of advanced gastric cancer. Since these systemic chemotherapies are adopted in patients with good performance status (PS), treatment for patients with poor PS remains controversial. Different approach are needed to improve quality of life (QOL), and prolong survival.
Biochemical modulation with leucovorin (LV), methotrexate (MTX) 1) , and CDDP 2) has shown to improve the effectiveness of 5-FU in gastric cancer.
Intra-arterial infusion of anticancer drugs are reported to increase local tissue levels and reduces systemic drug availability 3) . Theoretically, if the drug has a high extraction ratio, a high concentration of naive drug (noncombined to albumin) is delivered directly to the tumor. The potential for cell killing might be enhanced with less systemic exposure and less toxicity. Nakajima et al. found that the FLEP therapy, which consists of systemic delivery of 5-FU and leucovorin (LV) and intra-aortic infusion of CDDP and etoposide (ETP), yielded an overall response of 50% and a median survival time (MST) of 12.7 months 4) . To improve the effectiveness and decrease the side effects of chemotherapy for advanced gastric cancer, we hypothesized that intra-aortic frequent infusion of low-dose anticancer drugs and synchronized systemic administration of LV based on the triple biochemical modulation would be of therapeutic benefit in patients with advanced gastric cancer localized in the abdomen. We conducted a feasibility study to investigate whether synchronized intra-aortic chemotherapy (SIAC) would be safe and improve performance status of far-advanced gastric cancer patients with poor PS.
Preliminary Pharmacologic Studies
Materials and methods: Prior to this trial, pharmacokinetics of CDDP by intra-aortic infusion was studied on 4 patients with T3N3 Stage IIIC gastric cancer with informed consent. Under general anesthesia before laparotomy, the vascular access system (Vital-Port, COOK Vascular TM Inc.) was placed. The silicon catheter was inserted from femoral artery and placed in the aorta at the level of just under-edge of 11th thoracic vertebra, and then connected to the infusion port replaced subdermally in lower abdomen. After laparotomy, 20 mg of CDDP was administered from the port for one minute. Serial right gastro-epiploic artery (RGEA), vein (RGEV), peripheral artery (PA) and vein samples (5 ml for each) were drawn at baseline and repeated at 1, 2, 3, 5 and 10 minutes. The blood samples were immediately centrifuged (1000 g) for 10 minutes at 4 ℃ , and plasma was extracted and frozen at -20℃ until analysis. Four square centimeters of retroperitoneum were cut off at 5 and 10 minutes after CDDP injection. Just after gastrectomy, normal gastric mucosa and tumor tissue were cut off and frozen directly at -70℃ for later analysis. CDDP in plasma and tissue samples were measured by a previously described flameless atomic absorption spectrophotometry 5) . Briefly, ultra filtered plasma was centrifuged at 4℃ and the supernatant diluted (1:10 v/v) with water. Tissue sam-ples were digested overnight with concentrated HNO3 in screw-capped plastic tubes at 105℃ . The samples were incubated with H 2 O 2 for 1 h at 90℃ for further oxidation and background reduction. Deionized water was added a fixed volume. The standard platinum fluid was used H2PtC16 (Wako Pharm. Japan.). A 200-μl aliquot of the ultra filtered plasma and digested tissue were analyzed by atomic absorption spectrophotometer at 265.9 nm (Spectr AA 880 Zeeman, Balian technologies Japan Limited.). The detection limit of this flameless atomic absorption spectrophotometry assay for a 200-μl injection volume was 80 ng/ml in human plasma, and the coefficient of variation for the plasma concentration between 0.5 and 2 μg/ml was less than 4.1%.
Results: Peak levels of total CDDP were 7.4±1.8 μg/ ml in RGEA just after arterial infusion, 2.7±1.1 μg/ml in peripheral blood at one minute later and 1.73 μg/ml in RGEV at five minutes later. Each levels of total CDDP were almost same after 5 minutes ( Fig. 1 ). Gastric extraction rate of CDDP was 87.9±3.1% just after arterial infusion and tapered to -11.1±7.8% at 10 minutes later ( Table 1 ). Tissue concentration of CDDP in the retroperitoneum was 1.29 μg/g at 5 minutes after the arterial infusion and 0.49 μg/g at 120 minutes later while the gastrectomy was completed between the operations. Tissue concentrations of CDDP in the normal gastric mucosa and primary tumor were 0.48 and 0.56 μg/g respectively (Fig. 2) . These results revealed that most of CDDP in- fused intra-aortically were extracted in the stomach and retroperitoneal tissue immediately. On the other hand, peak level of free-CDDP was 6.5±1.5 μg/ml in RGEA and the ratio of free and total CDDP was 88.2±1.2% just after arterial infusion. The ratio tapered to 65.3±1.9% at 10 minutes later (Table 1 ). These data showed that the level of active free-CDDP in gastric tissue was high by intra-aortic infusion.
The pharmacological studies suggested that the naive and active form of anti-cancer drug could be safely delivered with high extraction rate by the intra-aortic infusion.
Patients and Eligibility Criteria
The eligibility criteria were histologically proven locally advanced Stage IV or recurrent carcinoma of the stomach, European Cooperative Oncology Group (ECOG) performance status 0-3; an estimated survival of at least 2 months, ≦ 80 years, serum creatinine ＜ 1.5 mg/dl, serum total bilirubin ＜ 1.6 mg/dl, absolute granulocyte counts ＞ 1500 cells/μl, platelet count ＞ 100,000/μl, hemoglobin ＞ 9 g/dl, no clinical manifestations of active cardiac or major vascular disease, no clinical evidence of CNS metastasis, no chemotherapy or radiotherapy within the previous 3 months, and no second malignancy. Written informed consent was received from all patients. Treatment were evaluated by three surgical and two medical oncologists, one pathologist, and one radiologist.
Assessment of Responses and Toxicity
Measurable lesions were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) 6) every 3 months. When primary tumors do not have measurable mass, we adopted the endoscopic evaluation criteria proposed by the Japanese Research Society of Gastric Cancer 7) which were also established by the World Health Organization (WHO) 8) .
Survival time was calculated from the start of chemotherapy (Kaplan-Meier). Tumor markers were not considered in the evaluation. Quality of life (QOL) was assessed by evaluating performance status (PS) immediately before instituting SIAC treatment and two weeks after the third cycle of SIAC.
Adverse reactions were classified according to the National Cancer Center Common Toxicity Criteria (NCI-CTC, version 2.0). In case of grade 3 hematological toxicity, dose of all drugs was reduced by 25%. In case of grade 3 gastrointestinal toxicity, only CDDP was reduced by 50%. The treatment was delayed for one or two weeks if there was no complete recovery from grade 3 or more leucopenia or thrombocytopenia.
Study design
Prior to the start of chemotherapy, a vascular access system (Vital-Port, COOK Vascular TM Inc.) was surgically installed under local anesthesia. The silicone catheter was introduced via a femoral artery and advanced until its tip rested in the aorta just below the inferior margin of the 11th thoracic vertebra. It was connected to the infusion port implanted sub-dermally in the lower abdomen. All patients received more than three cycles of chemotherapy. Treatment were continued until locoregional tumor progression or unacceptable toxicity.
Chemotherapy
The schedule is outlined in Figure 3 9) . After adequate venous access and appropriate hydration, undiluted solution of CDDP 6 mg/m 2 /body/day and MTX 6 mg/m 2 / body/day in 20 ml of 0.9% NaCl was administered IA through the port over one minute at 10 AM on days 1 to 5. Continuous intra-aortic infusion of 5-FU 150 mg/m 2 / body/day for 120 hours through an infusion pump with 5% glucose and 4000U of heparin was started immediately just after the MTX injection on days 1. L-LV 15 mg/m 2 /body/day in 100 ml of 0.9% NaCl was administered intravenously at 8 PM on days 2 to 6.
Chemotherapy were repeated every two weeks for the first three cycles, and every 4 weeks from the fourth to sixth cycles, every 8 weeks from the seventh to ninth cycles, and every 12 weeks from the tenth cycle, until tumor progression or unacceptable toxicity.
Statistical considerations
The primary end point of this phase II trial of SIAC was response rates. Changes in performance status was assessed as secondary end point. Response rates were compared with clinicopathologic characteristics by using the χ2 and log-rank tests. 
Results

Patient population and characteristics
Between January 1999 and December 2004, 59 consecutive patients with locally advanced Stage IV gastric cancer and 8 consecutive patients with recurrent gastric cancer were entered in this trial. Twenty five patients underwent gastrectomy as palliative therapy and thirty four patients did not receive gastrectomy. The rates of worse PS, greater tumor depth, and greater number of noncurable sites were higher in the latter group (Table 2) .
Response
The response rates by metastatic lesions are shown in Table 3 . The response rate was 61% (2 CR and 37 PR) and the tumor control rate (CR+PR+NC) was 89% in the 64 assessable patients. The response rate was 70% (30/43) for primary or local sites, 69% (8/13) for malignant ascites, 77% (20/26) in the liver and 65% (30/46) in the lymph nodes. There were no significant differences in response rates between the resected and non-resected cases. The response rate in recurrent cases was 38% which is lower than in the primary cases.
Changes in performance status
Mean of PS were significantly improved in primary cancer patients who received three or more cycles of SIAC, but not in recurrent patients. No patients had worse PS after SIAC treatment ( Table 4 ). Most of symptomatic improvement was food intake after the SIAC treatment. Fifty four % (32/59) of the primary cancer patients experienced clinically significant relief of tumorrelated symptoms.
Safety and Toxicity
All of 67 eligible patients were assessed for toxicity ( Table 5 ). No grade 4 toxicity was observed. Grade 3 toxicity were 8.9% (n=6) in anorexia, 4.5% (n=3) in leucopenia, and 3.0% (n=2) in nausea/vomiting. No grade 4 toxicity was observed.
Catheter-related complication developed in two cases. One is occlusion of catheter and the other is fever. No infection of the subcutaneous pocket for the port systems occurred. There were no thrombosis or bleeding related to the catheter or port systems.
Discussion
Approximately 35-40% of gastric cancer patients have lethal disease (primary tumor and metastases) confined to the abdominal cavity 10) . Therefore, it would be important for improving survival of patients with gastric cancer to control the tumor growth in the abdominal cavity. Intravenous systemic chemotherapy yields a considerable objective response and has been shown to have significant impact on survival. However, some patients with gastric cancer in the abdominal cavity are not good candidates for systemic chemotherapy because of gastrointestinal and bone marrow toxicity. A "first-pass effect" has been suggested to increase exposure of gastric cancer to chemotherapeutic agents and reduce toxicity 11) . Kitamura M et al. demonstrated a response rate of 29% to intra-aortic infusion therapy with sequential low-dose MTX/5-FU for advanced or recurrent gastric cancer with lesions localized to the abdominal cavity 12) . The FLEP (5-FU, LV, ETP, CDDP) regimen 13) , which consists of a combination of regional (ETP and CDDP intra-aortic) and systemic (5-FU and LV) delivery of chemotherapeutic agents, yielded a response rate of 40.8% and MST Objective response in liver and lymph nodes was assessed based on The response of primary lesions and malignant ascites was evaluated the Japanese Research Society for Gastric cancer . 14) . The pharmacokinetic rationale for the FLEP regimen was based on reports of the beneficial effects of intra-arterial chemotherapy 15) .
Preliminary pharmacokinetics study of CDDP in SIAC showed that the level of active free-CDDP in gastric tissue was high by intra-aortic infusion. The amount of accumulated CDDP in gastric tumor tissue resected at 2 hours after the intra-aortic infusion was 0.56 μg/g, it was almost same as that after the intravenous infusion of 50 mg/m 2 CDDP 16) . The extraction ratio was high just after intra-aortic infusion. It would provide first pass extraction. It seemed that the intra-aortic infusion therapy had small effect for systemic tumor. However, Stewart et al reported that intra-arterial administration of CDDP resulted in increased drug exposure of tumor in the infused area without substantially decreasing exposure of systemic tumor 15) .
Attempts to improve the efficacy of 5-FU have focused on the biochemical modulation. LV 17) , MTX 18) , and CDDP 19) have already been shown to modulate 5-FU. Nonrandomized clinical trials of 5-FU combined with LV 20) , MTX 21) , and CDDP 22) have yielded substantial rates of objective regression in patients with advanced gastric cancer. We hypothesized that continuously in-fused low-dose 5-FU could be modulated by sequential repeated administration of MTX and l-LV. Systemic administration of LV was expected to both rescue bone marrow suppression and provide synchronized modulation of 5-FU.
The results of the present study showed an objective response of 61%. The improvement rate of performance status was 50.7%, and the incidence of severe toxicity ( ≧ grade 3) was less than 9%. It is suggested that SIAC could control intra-abdominal carcinoma effectively with less systemic toxicity.
Current clinical studies of S-1 (TS-1), a novel oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, based on biochemical modulation of 5-FU have yielded response rates of 40-49%, an incidence of adverse events of 78% (40/51), with grade 3 to 4 of 20% 23) . A European phase II study showed that S-1 could be administered with an acceptable safety and toxicity but was associated with a moderate response rate similar to the rates achieved with other fluoropyrimidines 24) . However, these systemic studies of S-1 were the results for the patients with relative good condition (PS0-1) who could take oral drugs.
SIAC was initially intended to increase the anti-tumor effect by the two mechanisms. One was biochemical 
Mean of PS Changes in PS after SIAC
PS was evaluated immediately prior to SIAC and two weeks after the third cycle of SIAC. NCI-CTC, National Cancer Institute Common Toxicity Criteria Version 2.0. Table 5 Toxicity modulation of 5-FU by MTX and LV. The other was the first-pass effect of anticancer drugs. The significance of hepatic arterial infusion chemotherapy in liver metastases of colorectal cancer has been decreased because of the progress of systemic chemotherapy especially of molecular targeted drugs. Compared with colorectal cancer, the number of molecular targeted drugs available in gastric cancer is small.
Finding an effective chemotherapy regimen with novel drugs has also been important task in the treatment of advanced gastric cancer. However, intra-aortic synchronized administration with well-known conventional anticancer drugs such as CDDP, MTX, 5-FU and LV should be carefully conducted with less toxicity in patients with primary gastric cancer localized to the abdominal cavity, poor PS and symptomatic stage IV.
